Application of beta-elemene in preparation of medicine for treating endometriosis

By inhibiting ferritin and GPX4 expression through β-elene, blocking STAT3 and MAPK14 signaling pathways, inducing ferrode death in endometrial cells, solving the hormone-dependent and restricted fertility of endometriosis treatment in the prior art Problem, effective non-hormonal treatment effects have been achieved.

CN118903069APending Publication Date: 2024-11-08GUANGDONG NO 2 PROVINCIAL PEOPLES HOSPITAL
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411265244.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-10
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing drug treatment for endometriosis has side effects of inhibiting ovarian function and is not beneficial to fertility. There is no effective non-hormonal treatment plan, especially in the mechanisms related to iron overload and ferrodemort resistance have not been fully utilized.

Method used

通过β-榄香烯抑制铁蛋白FTH1和FTL的表达,抑制GPX4的表达和p-STAT3、p-MAPK14的磷酸化,逆转铁死亡抵抗,诱导异位子宫内膜细胞铁死亡,从而实现对子宫内膜异位症的治疗。

Benefits of technology

β-elene effectively induces ferrodynamic death in endometrial cells, reduces lesions, relieves dysmenorrhea and chronic pelvic pain, inhibits the formation of cysts and mass, and provides a treatment plan without inhibiting ovarian function, with minor side effects. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903069A_ABST
    Figure CN118903069A_ABST
Patent Text Reader

Abstract

The invention provides application of beta-elemene to prevention or treatment of endometriosis, and particularly relates to application of beta-elemene to preparation of a medicine or a preparation for preventing or treating endometriosis or application of beta-elemene to preparation of a medicine or a preparation for inducing ectopic endometrial cell ferroptosis. According to the application, the function of beta-elemene in endometriosis is found for the first time, particularly the expression inhibition effect of beta-elemene on ferritin FTH1 and FTL of ectopic endometrial cells and the influence of beta-elemene on GPX4, p-STAT3 and p-MAPK14 are found, and the effective treatment effect of beta-elemene on endometriosis is shown.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of biology and medicine technology, and specifically relates to an application of β-elemene in the preparation, treatment and prevention of endometriosis. Background Art

[0002] Endometriosis (EMs) refers to a chronic, complex disease in which the endometrium grows outside the uterine cavity, causing pain and infertility due to repeated bleeding. This disease affects about 10% to 15% of women of childbearing age, seriously endangering women's health. The treatment of EMs includes surgery and drug therapy. The drugs for EMs are mainly used to regulate hormones and inflammation, including combined oral contraceptives, progestins, anti-progestins, gonadotropin-releasing hormone agonists, gonadotropin-releasing hormone antagonists and aromatase inhibitors. The above drugs improve symptoms by inhibiting ovarian function, but can cause adverse reactions such as perimenopausal symptoms, and their use is restricted in women with fertility requirements. EMs patients are in urgent need of long-term non-hormonal treatment that does not affect fertility and has few side effects. From the above known drug treatment methods, current drug treatment has certain limitations. The clinical efficacy of traditional Chinese medicine on EMs has been widely recognized, and its biggest advantage is that it has no inhibitory effect on ovarian function. It is imperative to develop drugs for the treatment of endometriosis with good efficacy and few side effects by using modern pharmacological research methods and conducting in-depth research and screening on the active ingredients of natural products derived from traditional Chinese medicine.

[0003] Endometriosis is associated with iron overload and ferroptosis resistance. The local microenvironment of the ectopic lesions of ovarian endometriosis and the local microenvironment of the abdominal cavity are rich in free iron, which leads to enhanced resistance to ferroptosis in the ectopic endometrium, allowing it to grow in a high-iron environment and achieve ectopic implantation and proliferation of the endometrium. Focusing on iron overload and ferroptosis resistance, targeting ferroptosis of ectopic endometrial cells can provide a new strategy for the treatment of EMs. Ferritin is composed of ferritin heavy chain 1 (Heavy Polypeptide, FTH1) and ferritin light chain (FTL), which is responsible for the storage and release of free iron. Inhibiting the expression of FTH1 and FTL can further enhance the release of free iron, induce oxidative stress, and effectively induce ferroptosis. Therefore, targeting ferritin to induce ferroptosis can provide a non-hormonal treatment for endometriosis.

[0004] Curcumae Rhizoma extract, the main components of which include curcumol, curdione, curcumone, β-elemene, etc., has multiple pharmacological effects such as anti-tumor, anti-bacterial, and anti-thrombotic. β-elemene comes from traditional Chinese medicines such as Curcuma zedoaria and Curcuma zedoaria, and is a sesquiterpene compound with the chemical formula: C15H24, molecular weight: 204.35, CAS number: 20307-84-0. It has anti-tumor activity and has been widely used in the adjuvant treatment of tumors. Summary of the invention

[0005] In the prior art, β-elemene has been shown to have anti-tumor (lung cancer, gynecological tumors) and chemosensitivity-enhancing activities. However, there is no report on the relevant research that β-elemene can be used for the treatment of endometriosis.

[0006] In response to the above technical problems, the present application provides an application of β-elemene in anti-endometriosis drugs through the ferroptosis pathway. As a natural monomer, β-elemene can inhibit the expression of key ferritins FTH1 and FTL, inhibit GPX4 expression, phosphorylation of p-STAT3 and p-MAPK14, reverse ferroptosis resistance, and induce ferroptosis of ectopic endometrial cells, thereby realizing a new approach to combat endometriosis.

[0007] The specific technical solutions of this application are as follows:

[0008] The present application provides use of β-elemene in preventing or treating endometriosis.

[0009] Furthermore, the present application also provides the use of β-elemene in the preparation of a medicine or preparation for preventing or treating endometriosis.

[0010] Furthermore, the present application also provides the use of β-elemene in the preparation of a drug or preparation for inducing ferroptosis of ectopic endometrial cells.

[0011] Furthermore, the present application also provides the use of β-elemene in relieving dysmenorrhea and chronic pelvic pain caused by endometriosis.

[0012] Furthermore, the present application also provides the use of β-elemene in inhibiting cysts / lumps caused by endometriosis.

[0013] Furthermore, the endometriosis includes: ovarian endometriosis, pelvic endometriosis, deep infiltrating endometriosis, peritoneal endometriosis, and distant metastatic endometriosis.

[0014] Furthermore, the prevention or treatment of endometriosis or induction of ferroptosis of ectopic endometrial cells is achieved by inhibiting ferritin FTH1 and FTL, inhibiting the expression of glutathione peroxidase GPX4 or inhibiting the phosphorylation of p-STAT3 and p-MAPK14.

[0015] Furthermore, the amino acid sequence of the ferritin FTH1 is as described in SEQ NO:1; the amino acid sequence of the ferritin FTL is as described in SEQ NO:2; the amino acid sequence of the p-STAT3 is as described in SEQ NO:3; the amino acid sequence of the p-MAPK14 is as described in SEQ NO:4; and the amino acid sequence of the GPX4 is as described in SEQ NO:5.

[0016] Furthermore, the dosage of β-elemene is 0.1-20 mg / Kg of subject, preferably 4.15-12.5 mg / Kg of subject.

[0017] Furthermore, the present application also provides a pharmaceutical composition, which includes β-elemene, and the pharmaceutical composition is preferably used to prevent or treat endometriosis; or the pharmaceutical composition is preferably used to induce ferroptosis of ectopic endometrial cells; or the pharmaceutical composition is preferably used to relieve dysmenorrhea and chronic pelvic pain caused by endometriosis; or the pharmaceutical composition is preferably used to inhibit cysts / masses caused by endometriosis.

[0018] The present application provides a new application of β-elemene in medicine, and reveals that β-elemene and a drug combination containing elemene have the prospect of being developed into a drug for endometriosis, and has important social and economic value. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 This is a graph showing the results of detecting different β-elemene drug concentrations and action times to intervene in the viability of endometriosis epithelial cells (12Z) and ectopic endometrial stromal cells (ihESCs) in Example 1; wherein the abscissa is different concentration gradients of β-elemene (μg / ml), the ordinate is cell viability, and the drug action times are 24 hours, 48 ​​hours and 72 hours, respectively.

[0020] Figure 2 This is an ultramicroscopic transmission electron micrograph of the endometriosis epithelial cells (12Z) treated with β-elemene in Example 2; wherein Control is a blank control group, and β-ELE (70 μg / ml) is β-elemene at a concentration of 70 μg / ml.

[0021] Figure 3This is a result diagram of the analysis of the core target of β-elemene intervention in endometriosis epithelial cells (12Z) based on SPR mass spectrometry in Example 3; wherein, Figure 3 A is the workflow diagram of SPR mass spectrometry technology; Figure 3 B is the signal peak diagram of the flowing 12Z cell lysate, the sample on the chip surface and the blank area. The red signal curve in the figure represents the signal change in the β-elemene binding area on the chip, and the blue signal curve represents the signal change in the blank control area without sample on the chip. Figure 3 C is the heat map clustering result of the targets finally captured by SPR mass spectrometry sorted by Score (overall score) and Relative Quantity (relative abundance), with the score and abundance gradually decreasing from top to bottom.

[0022] Figure 4 These are the two-dimensional and three-dimensional result diagrams of the molecular docking of β-elemene with the core targets STAT3, MAPK14, GPX4, FTH1, and FTL in Example 4.

[0023] Figure 5 This is a result graph of the detection of the expression of core indicators of ferroptosis and ferroptosis of endometriosis epithelial cells (12Z) intervened by β-elemene in Example 5; wherein, β-ELE (70 μg / ml) is β-elemene at a concentration of 70 μg / ml, and Con is a blank control group; 12h is β-elemene intervention for 12 hours, 24h is β-elemene intervention for 24 hours, and 48h is β-elemene intervention for 48 hours; Era is Erastin at a concentration of 30 μg / ml, which is a positive control group. Figure 5 A shows that β-elemene inhibits the expression of GPX4, FTH1, and FTL proteins, and the phosphorylation of p-STAT3 and p-MAPK14; Figure 5 B is the levels of cellular ROS and lipid ROS after β-elemene intervention; Figure 5 C is the ferrous ion content of cells after intervention with β-elemene.

[0024] Figure 6 The figures are the results of detecting the lesion volume, H&E staining, Masson staining and Prussian blue DAB staining of β-elemene intervention in endometriosis mice in Example 6; wherein Mod is the model group, β-ELE (25 mg / kg) is the low-dose group of β-elemene, β-ELE (50 mg / kg) is the medium-dose group of β-elemene, β-ELE (75 mg / kg) is the high-dose group of β-elemene, and Dienogest (1 mg / kg) is 1 mg / kg of dienogest, which is the positive drug control group.

[0025] Figure 7The result diagram of detecting the expression of core indicators of ferroptosis and ferroptosis in mice with endometriosis by intervention with β-elemene in Example 6. Con is a blank control group, Mod is a model group, β-ELE 25 is a low-dose group of β-elemene at a dose of 25 mg / kg, β-ELE 50 is a medium-dose group of β-elemene at a dose of 50 mg / kg, β-ELE 75 is a high-dose group of β-elemene at a dose of 75 mg / kg, and DGST is a dienogest at a dose of 1 mg / kg, which is a positive drug group. DETAILED DESCRIPTION

[0026] The present application is further described below in conjunction with examples. It should be understood that the examples are only used to further describe and illustrate the present application and are not used to limit the present application.

[0027] Unless otherwise defined, the technical and scientific terms in this specification have the same meaning as those generally understood by those skilled in the art. Although similar or identical methods and materials as described herein may be used in experiments or practical applications, materials and methods are described herein below. In the event of a conflict, the present specification including the definitions therein shall prevail. In addition, materials, methods and examples are provided for illustration only and are not restrictive. The present application is further described below in conjunction with specific embodiments, but is not intended to limit the scope of the present application.

[0028] The present application provides a use of β-elemene in preventing or treating endometriosis.

[0029] Specifically, the β-elemene described in the present application is derived from traditional Chinese medicines such as Curcuma aromatica and Curcuma zedoaria, and its chemical formula is C15H24, and its chemical structure is shown in Formula 1.

[0030]

[0031] The β-elemene described in the present application can be a commercially available product such as β-elemene (CAS No.: 20307-84-0) produced by Shanghai Taoshu Biotechnology Co., Ltd., or can be prepared by chemical and biological methods in the prior art.

[0032] The present application further provides the use of β-elemene in preparing a drug or agent for preventing or treating endometriosis.

[0033] In a specific embodiment, the endometriosis includes ovarian endometriosis, pelvic endometriosis, deep infiltrating endometriosis, peritoneal endometriosis, and distant metastatic endometriosis.

[0034] The present application also provides the use of β-elemene in inducing ferroptosis of ectopic endometrial cells.

[0035] The present application further provides the use of β-elemene in the preparation of a drug or preparation for inducing ferroptosis of ectopic endometrial cells. The cell ferroptosis is a special form of cell death associated with iron metabolism disorders, which is a programmed death that occurs in cells under specific conditions through a series of complex biochemical reactions. The occurrence of cell ferroptosis depends on the accumulation of intracellular iron, and under the action of ferrous iron or esteroxygenase, catalyzes lipid peroxidation of highly expressed unsaturated fatty acids on the cell membrane, resulting in oxidative damage to membrane lipids, which is manifested as a decrease in the expression or inactivation of antioxidant systems (such as glutathione GSH and glutathione peroxidase GPX4).

[0036] In a specific embodiment, β-elemene targets ferritin FTH1 and FTL, and inhibits the expression of ferritin FTH1 and FTL to induce ferroptosis of ectopic endometrial cells. The ferritin FTH1 is a ferritin heavy chain 1, which stores iron in a soluble form through ferroxidase activity, promotes the oxidation of divalent iron, and deposits it in the form of ferric hydroxide to achieve iron homeostasis and maintain iron. The ferritin FTH1 also participates in the storage of iron in cells. The ferritin FTL is a ferritin light chain, which together with the ferritin heavy chain FHL constitutes a complete ferritin structure. The ferritin FTL is composed of a protein shell (apoferritin) and an iron core to form a spherical shell structure, which is conducive to iron entering through pores. Ferritin FTL stores iron in a soluble, non-toxic form in ferritin and transports it to cells. At the same time, ferritin FTL participates in maintaining the body's iron homeostasis by controlling the storage and release of iron, ensuring the effective use of iron in cells and avoiding iron overload.

[0037] In a specific embodiment, β-elemene inhibits STAT and MAPK pathways by inhibiting the phosphorylation of p-STAT3 and p-MAPK14. STAT3 is a transcription factor, and its phosphorylation is a key step in activating its transcriptional activity. Inhibiting the phosphorylation of p-STAT3 can block the activation of the STAT3 signaling pathway, thereby inhibiting processes such as cell proliferation, anti-apoptosis and immune escape mediated by this pathway. p-MAPK14 is a stress-activated protein kinase, and its phosphorylation plays an important role in processes such as inflammatory response, cell apoptosis and cell cycle regulation. Inhibiting the phosphorylation of p-MAPK14 can block the activation of the MAPK signaling pathway, thereby inhibiting processes such as inflammatory response and cell apoptosis mediated by this pathway.

[0038] In one embodiment, β-elemene inhibits the expression of GPX4. Glutathione peroxidase 4 (GPX4) plays a key role in reversing ferroptosis resistance. As a key resistance factor to ferroptosis, GPX4 prevents the toxicity of lipid peroxides through its enzymatic activity and maintains the homeostasis of the membrane lipid bilayer, thereby protecting cells from the threat of ferroptosis.

[0039] In a specific embodiment, the prevention or treatment of endometriosis described in the present application is achieved by targeting the ferritins FTH1 and FTL of ectopic endometrial cells and inhibiting the expression of ferritins FTH1 and FTL to induce ferroptosis of ectopic endometrial cells.

[0040] In a specific embodiment, the prevention or treatment of endometriosis described in the present application is achieved by inhibiting the phosphorylation of p-STAT3 and p-MAPK14 of ectopic endometrial cells, thereby inhibiting their STAT and MAPK pathways, thereby inducing ferroptosis of ectopic endometrial cells.

[0041] In a specific embodiment, the prevention or treatment of endometriosis described in the present application is achieved by targeting the glutathione peroxidase GPX4 of ectopic endometrial cells and inhibiting the expression of GPX4 to induce ferroptosis of ectopic endometrial cells.

[0042] In a specific embodiment, the amino acid sequence of the ferritin FTH1 is as described in SEQ NO:1; the amino acid sequence of the ferritin FTL is as described in SEQ NO:2; the amino acid sequence of the p-STAT3 is as described in SEQ NO:3; the amino acid sequence of the p-MAPK14 is as described in SEQ NO:4; and the amino acid sequence of the GPX4 is as described in SEQ NO:5.

[0043] In a specific embodiment, the dosage of β-elemene is 0.1 to 20 mg / Kg of subject, preferably 4.15 to 12.5 mg / Kg of subject.

[0044] Furthermore, the present application also provides a pharmaceutical composition, which includes β-elemene, and the pharmaceutical composition is preferably used to prevent or treat endometriosis; or the pharmaceutical composition is preferably used to induce ferroptosis of ectopic endometrial cells; or the pharmaceutical composition is preferably used to relieve dysmenorrhea and chronic pelvic pain caused by endometriosis; or the pharmaceutical composition is preferably used to inhibit cysts / masses caused by endometriosis.

[0045] In a specific embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier or excipient.

[0046] Specifically, the above-mentioned pharmaceutically acceptable carriers include binders, buffers, antioxidants, solubilizers, thickeners, lubricants, disintegrants, diluents, stabilizers, preservatives, colorants, flavoring agents, dissolution aids, emulsifiers, isotonic agents and the like.

[0047] The present application also provides a method for preventing or treating endometriosis, comprising administering an effective dose of β-elemene to a subject, preferably the effective dose is 0.1 to 20 mg / Kg of the subject, more preferably 4.15 to 12.5 mg / Kg of the subject.

[0048] In one embodiment, the method provided herein comprises administering the drug orally or by injection to a subject.

[0049] The effective dose described herein refers to an amount sufficient to achieve the desired therapeutic results or to have an effect on undesirable symptoms but not sufficient to cause harmful side effects, and can be easily determined by those skilled in the art.

[0050] In a specific embodiment, the dosage administered to a subject varies depending on the administration route, symptoms, patient age, etc., and can be determined by a clinician.

[0051] Example

[0052] The following is a detailed description of the implementation methods of the present application through specific examples, but the following content should not be construed as limiting the present application in any way. The substances used in the examples are all commercially available products unless otherwise specified.

[0053] Example 1

[0054] source:

[0055] β-elemene (purchased from Shanghai Taoshu Biotechnology Co., Ltd., CAS No.: 20307-84-0).

[0056] Immortalized human endometriosis cell line 12Z (purchased from Zhejiang Meisen Cell Technology Co., Ltd.).

[0057] Human endometriosis immortalized stromal cell line ihESCs (purchased from Xiamen Yimo Biotechnology Co., Ltd.).

[0058] Example 1 Effect of β-elemene on the cell viability of ectopic endometrial epithelial cells (12Z) and ectopic endometrial stromal cells (ihESCs) in endometriosis.

[0059] After β-elemene is dissolved in dimethyl sulfoxide (DMSO), it is diluted with basal culture medium or PBS and mixed evenly. The immortalized human endometriosis cell line (12Z) and the immortalized human endometriosis stromal cell line (ihESCs) are used as in vitro system models for studying endometriosis. The immortalized human endometriosis cell line (12Z) and the immortalized human endometriosis stromal cell line (ihESCs) are both cultured in DMEM / F12 complete culture medium (12% FBS + 1% double antibody) and placed in a humidified incubator at 37°C and 5% CO2 for routine culture. After the cell growth density reaches 80-90%, 0.25% trypsin digestion for 1-2 minutes and then complete culture medium is used to stop digestion. After centrifugation, the cells are resuspended and passaged or inoculated at a ratio of 1:2 for standby use. Immortalized human endometriosis cell line (12Z) and immortalized human endometriosis stromal cell line (ihESCs) were cultured at 5×10 3 / well density was inoculated in a 96-well plate, and after overnight adherence, different concentration gradients of β-elemene (10μg / ml-100μg / ml) were added for treatment for 24h, 48h, and 72h, respectively. The effect of β-elemene on cell viability was detected by CCK8.

[0060] like Figure 1 As shown, β-elemene can induce endometriosis epithelial and stromal cell death in vitro in a time- and concentration-dependent manner. 70 μg / ml β-elemene began to significantly inhibit the viability of endometriosis epithelial cells, and 40 μg / ml β-elemene began to significantly inhibit the viability of endometriosis stromal cells.

[0061] Example 2: Effects of β-elemene on the ultrastructure of endometriotic epithelial cells (12Z).

[0062] Immortalized human endometriosis cell line (12Z) was cultured at 5×10 5 / pore density was inoculated in a 100 mm culture dish, and after overnight attachment, β-elemene (β-ELE 70 μg / ml) was added for 48 hours. The blank control group was cultured conventionally. The cells were collected by digestion and centrifugation, and fixed and preserved in electron microscope fixative. After preparation by transmission electron microscopy, the ultrastructural changes were observed under a transmission electron microscope.

[0063] like Figure 2As shown in the figure, Control is the blank control group, and β-ELE 70μg / ml is the ultrastructural changes of 12Z cell line after 48h intervention with 70μg / ml dose of β-elemene. After β-elemene intervened in endometriotic epithelial cells, the cells mainly showed mitochondrial shrinkage, reduced volume, thickened membrane density, unclear mitochondrial cristae structure, and more autophagosomes and autophagic lysosomes, which are consistent with the morphological changes of ferroptosis and ferroptosis reported in the literature, indicating that β-elemene can induce ferroptosis of endometriotic cells.

[0064] Example 3: SPR mass spectrometry analysis technology was used to identify the core target of β-elemene in regulating ferroptosis.

[0065] Surface plasmon resonance (SPR) analysis is an optical detection method used to study the interaction of ligand binding with membrane proteins, which is a major goal of drug research and development. This technology can provide significant benefits when performing affinity and kinetic measurements of biomolecular interactions. Since SPR can only analyze the binding process, techniques have been developed to combine SPR with mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy to also detect bound molecules. In this study, SPR combined with mass spectrometry was used to identify the core target (protein) of β-elemene in regulating ferroptosis in the 12Z cell line.

[0066] The SPR experimental method is:

[0067] Cell lysate sample processing and photo-crosslinking sensor chip preparation: Collect at least 1×10 712Z cells, centrifuge briefly to concentrate the sample at the bottom of the EP tube, add 120μL PBS and cocktail protease inhibitor with a final concentration (v:v) of 1%, shake and resuspend thoroughly, add BWLS-17 lysis buffer at a ratio of 3:4, treat the cell sample according to the jet lysis method SOP, centrifuge the treated sample at 16000g, 10min, 4℃, and store it in a -40℃ refrigerator. Thaw the sample before testing, centrifuge at 16000g, 10min, 4℃, and take the supernatant for concentration determination. Take out a photo-crosslinking sensor chip and warm it to room temperature for 30min. Prepare β-elemene with DMSO to make a 10μM solution. Spot the compound solution on the designated area on the 3D photo-crosslinking sensor chip by a high-throughput array printer. Using a double-needle printing system, the chip surface contains 50×50 dots, the expected spot solution volume is 2.5nL, and the spotting is repeated 5 times, and the spotting volume on the chip surface is 31.25μL. During the period, strictly avoid light, N2 environment, pressure 1.05ATMs. After printing, the chip is naturally dried in the chip printer under low temperature dehumidification. After drying, the chip is transferred to the UV crosslinker for photocrosslinking reaction, wavelength 365nm, N2 environment pressure 1.20ATMs, irradiation process and parameters: energy 9000μW / cm, 2min; pause 2min; energy 9000μW / cm, 2min; pause 2min; energy 2500μW / cm, 15min. After the photocrosslinking reaction, shake and wash with DMF, anhydrous ethanol and ultrapure water on a shaker for 15min. Use nitrogen to blow dry in the clean workshop, stick the chip with Cover, mark the chip for standby, and the sensor chip is now completed, and the storage condition is -20℃.

[0068] SPR online capture of target: After installing the chip on the SPR biochip analysis system, adjust the test baseline, regenerate the chip surface three times, the circulating regeneration solution is Gly·HCl (pH2.0), flow rate (Rate): 3μL / s, duration (Duration): 300s, carrier buffer (Buffer): 1×PBST (0.05% Tween-20); block the chip surface with 100μg / mL BSA, flow rate (Rate): 3μL / s, duration (Duration): 300s, carrier buffer (Buffer): 1×PBS (pH7.4); regenerate the chip surface Regen*1 time, the regeneration solution is Gly·HCl (pH 2.0), flow rate (Rate): 3μL / s, duration (Duration): 300s; after completing this step, return the timeline and signal baseline to zero. 1×PBS (pH7.4) buffer was circulated to balance the system, flow rate (Rate): 2μL / s, duration (Duration): 260s, carrier buffer (Buffer): 1×PBS (pH7.4); the prepared cell lysate sample was passed into the chip to complete the online capture process, flow rate (Rate): 2μL / s, duration (Duration): 260s, carrier buffer (Buffer): 1×PBS (pH7.4).

[0069] The method of LC-MS mass spectrometry analysis is:

[0070] In situ Trypsin digestion of chip protein: Perform FASP digestion on the protein chip: drain the buffer in the chip, add DTT solution with a final concentration of 10mM to the chip through the sample pump, and incubate at 56℃ for 1h for reduction reaction; after reduction, continue to pump IAM (iodoacetamide) solution to make the final concentration of 55mM, and incubate at room temperature in the dark for 45min; collect the cleavage system in the chip and filter through a 0.22μm filter membrane (online cleavage process is completed). Remove the chip, add 30uL 0.25M TEAB (tetraethylammonium bromide) for replacement cleaning and rewash 2 to 3 times; add 30uL 0.5M TEAB (tetraethylammonium bromide), add trypsin (trypsin is stored in 50mM acetic acid, the storage concentration is 1ug / uL), add trypsin at a ratio of trypsin: substrate protein = 1:20, mix well, incubate at 37°C overnight, add enzyme solution at a ratio of trypsin: substrate protein = 1:20, and incubate at 37°C for 4h; take out the digested peptide solution into a 1.5mL collection tube, add 30uL 0.5M TEAB iodoacetamide (enzymatic hydrolysis process is completed), and combine with the previous filtrate, vacuum dry and set aside.

[0071] LC-MS protein identification: The peptides were dissolved in 10μl mobile phase A, and 8μl was loaded after dissolution. The loading flow rate was 10μl / min, and the loading time was 3 minutes. The peptides were directly captured by the capture column, and the salt solution passing through the capture column was directly discharged into the waste liquid. After the valve was switched, the capture column and the analytical column were connected, and the Nano pump was started for RP separation, and the mass spectrometry acquisition was started for online detection of peptides. From 2% B to 45% B within 60 minutes, the reverse phase process took a total of 60 minutes, the flow rate was 300nL / min, and the column temperature was 40°C.

[0072] Mass spectrometry analysis: Full scan MS was scanned using the SCIEX MALDI-TOF / TOF system with a scan time of 90 min, a scan range of 350-1600 m / z, and a resolution of 70,000 (at m / z 200). The ion source parameters were GS1: 50; GS2: 50; CUR: 30; TEM: 550; the ISVF default values ​​remained unchanged, the method selected was MS Method, the scan type was TOF MS, the polarity was Positive, the calibration scheme was Auto Calibration, the TOF Masses range Max could be set to 1500 Da, and the scan range was automatically controlled according to the parent ion mass-to-charge ratio. The top 25 ions were selected for automatic MS / MS in subsequent experiments, where each MS / MS event included a 100 millisecond scan. The parent ion selection criteria included intensity, ions greater than 150 counts / s, and charge states greater than 2. MS data were collected using SCIEX OS Software (AB Sciex Pte. Ltd). The above flow chart is shown in the figure below. Figure 3 As shown in A.

[0073] like Figure 3 As shown in the data, a total of 76 proteins were identified during the action of β-elemene on 12Z cells. Combined with the heat map cluster analysis and molecular docking results, it was finally determined that STAT3, MAPK14, FTH1, FTL, and GPX4 were the key targets of β-elemene in regulating ferroptosis of endometriotic epithelial cells (12Z).

[0074] Example 4: Molecular docking was used to analyze the interaction between β-elemene and core targets STAT3, MAPK14, FTH1, FTL, and GPX4.

[0075] The crystal structure files of FTH1 protein (PDB ID: 1FHA), FTL protein (PDB ID: 6TR9), GPX4 protein (PDB ID: 6HN3), STAT3 protein (PDB ID: 6NJS) and MAPK14 (PDB ID: 3HLL) were downloaded from the RCSB PDB database. The protein crystal structure was preprocessed using the PyMOL program to remove heteroatoms (solvents, small molecules, etc.) in the protein, repair the incomplete structure, and obtain the protein structure to be docked. The processed STAT3, MAPK14, FTH1, FTL and GPX4 proteins were docked with the β-elemene molecule using the AutoDock Vina 1.2.5 program. Since the docking site is unknown, the protein needs to be docked globally. The default value of the spacing parameter of the calculation grid in AutoDock Vina is used, that is, it is set to 0.375; the default value of the exhaustiveness parameter is used, that is, it is set to 8. The processed PDBqt files of the protein and the small molecule are input into AutoDock Vina, and the molecular docking is performed according to the parameters set above. After docking is completed, the docked conformations are sorted according to their scores, and the optimal structure is selected for analysis.

[0076] like Figure 4 As shown, β-elemene binds to amino acid residues TYR-32, LEU-35, ARG-63, and ILE-85 of FTH1 to form three groups of hydrophobic interactions to stabilize the structure. β-elemene binds to FTL at amino acid sites ALA-61, LYS-62, TYR-27, PHE-137, and LEU-144. β-elemene binds to amino acid residues TYR-169, PHE-170, PRO-167, VAL-36, and LYS-145 of GPX4. β-elemene binds to amino acid residues VAL-490, LEU-438, LYS-370, HIS-437, and LYS-383 of STAT3. β-elemene binds to amino acid residues ALA-255, LEU-195, TRP-197, PRO-191, LEU-291, ILE-250 and LEU-246 of MAPK14 to stabilize the binding conformation. β-elemene has good binding affinity with STAT3, MAPK14, FTH1, FTL and GPX4.

[0077] Example 5: In vitro experiments confirmed that β-elemene can effectively induce ferroptosis of endometriotic epithelial cells.

[0078] Endometriosis epithelial cells (12Z) were routinely cultured and the culture medium was discarded. The cells were washed twice with PBS, and 50-60ul of RAPI lysis solution was added to each well of a six-well plate. The cells were placed on ice for lysis for 30 minutes. The lysed cells were scraped with a cell scraper and collected into a centrifuge tube. The cells were centrifuged in a precooled centrifuge at 12000rpm for 12 minutes at 4℃. The total protein concentration was detected by BCA method, and RAPI was diluted to the same concentration, and loading buffer was added. The cells were heated at 95℃ for 10 minutes for denaturation, and stored in a refrigerator at -80℃ for subsequent experiments. The expression of FTH1, FTL, GPX4, STAT3, p-STAT3, Anti-p38 alpha / MAPK14 antibody, and p-38 (p-MAPK14) proteins was detected by Western blot.

[0079] Dilute DCFH-DA with serum-free culture medium at a ratio of 1:1000 to a final concentration of 10 μmol / L. Remove the cell culture medium and add an appropriate volume of diluted DCFH-DA. The added volume should be sufficient to cover the cells. Incubate in a 37°C cell culture incubator for 20 minutes. Wash the cells three times with serum-free cell culture medium to fully remove the DCFH-DA that has not entered the cells. Collect the cells loaded with probes in situ after conventional trypsin digestion, resuspend in PBS, and detect the fluorescence intensity of each group by flow cytometry. The fluorescence spectrum of DCF is similar to that of FITC, and DCF is detected using the parameter settings of FITC. Set the groups, set β-elemene intervention for 0h, 12h, 24h, and 48h, and set two groups of sample wells for each group. Sample A: No additives (12Z cells only). Sample B: 12Z cells with added iron (ferric ammonium sulfate). 100 μl of 12Z cell suspension was inoculated on a 96-well black plate to reach 10,000 cels / well, and cultured overnight in a 37°C 5% CO2 incubator. The cells of sample B were washed 3 times with 100 μl of DMEM / F12. 100 μl of ferrous sulfate / DMEM / F12 was added to sample B and allowed to stand in a 37°C, 5% CO2 incubator for 30 minutes. The cells in all wells were washed 3 times with 100 μl of HBSS. 100 μl of HBSS solution containing FerroOrange (final concentration: 1 μmol / L) was added to samples A and B and cultured in a 37°C, 5% CO2 incubator for 30 minutes. The fluorescence intensity of each sample was detected using a multi-function plate reader (Ex: 543 nm, Em: 580 nm).

[0080] like Figure 5The results show that β-elemene has a good therapeutic effect at 70 μg / ml, and can inhibit the occurrence and development of endometriosis by dephosphorylating STAT3 and p38alpha / MAPK14 and regulating the phosphorylation kinase pathway. In addition, β-elemene can reduce the expression of GPX4, FTH1, and FTL proteins, thereby inducing ferroptosis ( Figure 5 A). ROS and lipid ROS levels in 12Z cells increased after β-elemene intervention ( Figure 5 B); The ferrous ion kit detected the ferrous ion expression of β-elemene, indicating that after the intervention of β-elemene, the ferrous ion expression in cells increased ( Figure 5 C), confirming that β-elemene is associated with the induction of ferroptosis.

[0081] Example 6: A classic endometriosis disease model was constructed using wild-type C57BL / 6 mice, and β-elemene was intraperitoneally administered to observe its regulatory effects on endometriosis lesions and induced ferroptosis in mice.

[0082] Construction of a classic allogeneic transplantation mouse model of endometriosis disease: donor mice were anesthetized by isoflurane inhalation, the donor mouse endometrium was isolated and obtained, and the endometrial fragment suspension was prepared and implanted into the abdominal cavity of the recipient mouse. After modeling, the recipient mouse was intraperitoneally injected with 3 μg of estradiol benzoate every 3 days to promote the colonization of endometrial fragments, and the model was used continuously for 3 weeks. The volume of the transplanted lesions increased, transparent cystic ectopic lesions were visible in the peritoneum, with clear or yellow fluid accumulation, soft texture, and microangiogenesis around the lesions. HE staining showed that endometrial glandular epithelial structures were visible in the lesions, and interstitial cells were visible under the glands, which was the standard for successful modeling.

[0083] After establishing the mouse model of endometriosis, β-elemene (low dose 25 mg / kg / day; medium dose 50 mg / kg / day; high dose 75 mg / kg / day, intraperitoneal injection), positive control group (dienogest, 1 mg / kg / day, gavage), model group (normal saline, 0.2 ml / mouse / day, gavage) were given for 3 consecutive weeks. After the last administration, the mice were euthanized and the uterus and ectopic endometrial lesions were collected. The length, width and height of the lesions were recorded with an electronic vernier caliper to evaluate the changes in lesion volume. After the tissue was rinsed in PBS solution, it was dried and spread on filter paper, fixed with paraformaldehyde for 24 hours, dehydrated, waxed, and embedded in paraffin. After obtaining the slices, HE staining was used, and the tissue pathology was observed under a microscope after preparation. Masson staining was used to detect the deposition of collagen fibers in the lesion tissue; Prussian blue DAB staining was used to detect iron death in the lesion tissue. Mouse uterus and ectopic lesion tissue specimens were obtained, and tissue lysis buffer was added to fully homogenize and centrifuged to obtain protein supernatant. Samples were prepared after BCA quantification, and Western Blotting was performed to detect the expression of FTH1, FTL, GPX4, STAT3, and MAPK14 proteins in mouse ectopic lesion tissues.

[0084] like Figure 6 and Figure 7 As shown in the results, after intervention with β-elemene, the number and volume of ectopic lesions decreased, confirming that β-elemene can inhibit the growth of ectopic lesions in EMs. HE staining showed that ectopic endometrial glands could be seen growing in the lesions of EMs mouse model, and β-elemene monomer and dienogest could inhibit the growth of ectopic lesions and glands. Masson staining showed that the fibrosis level of ectopic lesions decreased after intervention with β-elemene, and β-elemene could inhibit the fibrosis of ectopic lesions; Prussian blue DAB staining results showed that after intervention with β-elemene, the yellow staining gradually increased, which could induce ferroptosis of lesions, thereby inhibiting the growth of ectopic lesions. β-elemene could inhibit the phosphorylation of STAT3 and MAPK14 in ectopic lesions, and induce ferroptosis of ectopic lesions by inhibiting the expression of ferritin FTH1, FTL and GPX4, thereby inhibiting the occurrence and development of endometriosis.

[0085] The above is only the preferred experimental example of the present application, and does not limit the present application in other forms. Any technician familiar with the profession may use the technical content disclosed above to change or modify it into an equivalent experimental example with equivalent changes. However, any simple modification, equivalent change and modification made to the above experimental examples based on the technical essence of the present application without departing from the content of the technical solution of the present application still falls within the protection scope of the technical solution of the present application.

Claims

1. Use of β-elemene in preventing or treating endometriosis.

2. Use of β-elemene in the preparation of medicines or preparations for preventing or treating endometriosis.

3. Use of β-elemene in the preparation of medicines or preparations for inducing ferroptosis of ectopic endometrial cells or reversing ferroptosis resistance.

4. The use of β-elemene in relieving dysmenorrhea and chronic pelvic pain caused by endometriosis.

5. The use of β-elemene in inhibiting cysts / masses caused by endometriosis.

6. The use according to any one of claims 1 to 5, wherein The prevention or treatment of endometriosis or the induction of ferroptosis of ectopic endometrial cells is achieved by inhibiting the expression of ferritin FTH1 and FTL, inhibiting the expression of glutathione peroxidase GPX4, or inhibiting the phosphorylation of p-STAT3 and p-MAPK14.

7. The use according to claim 6, wherein The amino acid sequence of the ferritin FTH1 is as shown in SEQ NO: 1; The amino acid sequence of the ferritin FTL is as shown in SEQ NO: 2; The amino acid sequence of p-STAT3 is as described in SEQ NO:3; The amino acid sequence of p-MAPK14 is as described in SEQ NO:4; The amino acid sequence of the glutathione peroxidase GPX4 is as shown in SEQ NO:

5.

8. The use according to any one of claims 1 to 7, wherein The dosage of the β-elemene is 0.1-20 mg / kg of the subject.

9. A pharmaceutical composition comprising β-elemene, preferably the pharmaceutical composition is used to prevent or treat endometriosis; or preferably the pharmaceutical composition is used to induce ferroptosis of ectopic endometrial cells; or preferably the pharmaceutical composition is used to relieve dysmenorrhea and chronic pelvic pain caused by endometriosis; or preferably the pharmaceutical composition is used to inhibit cysts / masses caused by endometriosis.

Citation Information

Cited By

  • Fingerprint spectrum and multi-component simultaneous determination method for atractylodes macrocephala koidz medicinal material and extract thereof

    CN121090716A